JoVE Visualize What is visualize?
Stop Reading. Start Watching.
Advanced Search
Stop Reading. Start Watching.
Regular Search
Find video protocols related to scientific articles indexed in Pubmed.
Treatment and outcomes of metastatic colorectal cancer in Australia: defining differences between public and private practice.
Intern Med J
PUBLISHED: 11-05-2014
Show Abstract
Hide Abstract
Prior studies have suggested improved outcomes for cancer patients managed in private centres, despite universal health care within Australia.
Related JoVE Video
Current opinion on optimal systemic treatment for metastatic colorectal cancer: outcome of the ACTG/AGITG expert meeting ECCO 2013.
Expert Rev Anticancer Ther
PUBLISHED: 08-20-2014
Show Abstract
Hide Abstract
The treatment of metastatic colorectal cancer has evolved greatly in the last 15 years, involving combined chemotherapy protocols and, in more recent times, new biologic agents. Clinical benefit from the use of targeted therapy with bevacizumab, aflibercept, cetuximab, panitumumab and regorafenib in the treatment of metastatic colorectal cancer is now well established with median overall survival accepted as over 24 months, and with super selection for extended RAS patients higher again. The optimal timing of treatment options requires careful consideration of predictive biomarkers, and importantly the potential for interactions, to derive the maximal benefit. A group of colorectal subspecialty medical oncologists from Australia, the USA, the Netherlands and Germany met during ECCO 2013 to discuss current practice. Subsequent new data from the American Society of Clinical Oncology were also reviewed. This article reviews the evidence discussed in support of modern treatments for colorectal cancer and the decision-making behind the treatment choices, with their benefits and risks.
Related JoVE Video
PIK3CA, BRAF and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer - results from NCIC CTG / AGITG CO.17.
Clin. Cancer Res.
PUBLISHED: 11-11-2013
Show Abstract
Hide Abstract
Cetuximab improves survival in patients with K-ras wild-type advanced colorectal cancer (CRC). We examined the predictive and prognostic significance of additional biomarkers in this setting, in particular BRAF, PIK3CA and PTEN.
Related JoVE Video
Quality of life in patients with K-RAS wild-type colorectal cancer: The CO.20 Phase 3 Randomized Trial.
Cancer
PUBLISHED: 07-16-2013
Show Abstract
Hide Abstract
The CO.20 trial randomized patients with K-RAS wild-type, chemotherapy-refractory, metastatic colorectal cancer to receive cetuximab (CET) plus brivanib alaninate (BRIV) or CET plus placebo (CET/placebo).
Related JoVE Video
Phase III randomized, placebo-controlled study of cetuximab plus brivanib alaninate versus cetuximab plus placebo in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal carcinoma: the NCIC Clinical Trials Group and AGITG CO.20 Tr
J. Clin. Oncol.
PUBLISHED: 05-20-2013
Show Abstract
Hide Abstract
The antiepidermal growth factor receptor monoclonal antibody cetuximab has improved survival in patients with metastatic, chemotherapy-refractory, wild-type K-RAS colorectal cancer. The addition of brivanib, a tyrosine kinase inhibitor targeting vascular endothelial growth factor receptor and fibroblast growth factor receptor, to cetuximab has shown encouraging early clinical activity.
Related JoVE Video
Current opinion on optimal treatment for colorectal cancer.
Expert Rev Anticancer Ther
PUBLISHED: 04-27-2013
Show Abstract
Hide Abstract
The medical treatment of colorectal cancer (CRC) has evolved greatly in the last 10 years, involving complex combined chemotherapy protocols and, in more recent times, new biologic agents. Advances in adjuvant therapy have been limited to the addition of oxaliplatin and the substitution of oral fluoropyrimidine (e.g., capecitabine) for intravenous 5-fluorouracil with no evidence for improved outcome with biological agents. Clinical benefit from the use of the targeted monoclonal antibodies, bevacizumab, cetuximab and panitumumab, in the treatment of metastatic CRC is now well established, but the optimal timing of their use requires careful consideration to derive the maximal benefit. Evidence to date suggests potentially distinct roles for bevacizumab and EGF receptor-targeted biological agents (cetuximab and panitumumab) in the treatment of metastatic CRC. This article reviews the evidence in support of modern treatments for CRC and the decision-making behind the treatment choices, their benefits and toxicities.
Related JoVE Video
Competing on talent analytics.
Harv Bus Rev
PUBLISHED: 10-09-2010
Show Abstract
Hide Abstract
Do investments in your employees actually affect workforce performance? Who are your top performers? How can you empower and motivate other employees to excel? Leading-edge companies such as Google, Best Buy, Procter & Gamble, and Sysco use sophisticated data-collection technology and analysis to answer these questions, leveraging a range of analytics to improve the way they attract and retain talent, connect their employee data to business performance, differentiate themselves from competitors, and more. The authors present the six key ways in which companies track, analyze, and use data about their people-ranging from a simple baseline of metrics to monitor the organizations overall health to custom modeling for predicting future head count depending on various "what if" scenarios. They go on to show that companies competing on talent analytics manage data and technology at an enterprise level, support what analytical leaders do, choose realistic targets for analysis, and hire analysts with strong interpersonal skills as well as broad expertise.
Related JoVE Video
A naturalistic evaluation of psychosocial interventions for cancer patients in a community setting.
J Psychosoc Oncol
PUBLISHED: 04-15-2010
Show Abstract
Hide Abstract
We used a naturalistic methodology to examine associations between change in cancer patients emotional functioning and their use of interventions in a community organization. One-hundred ninety-two patients completed measures at baseline and 6 months later. During this time, they utilized the organizations various interventions as they wished. Attendance at educational events was associated with decreased well-being. Use of art therapy groups was not associated with decreases in negative emotion but was consistently associated with increases in positive emotion. Improved functioning on some measures was associated with use of psychoeducational groups, expressive/supportive groups, movement classes, healing arts, and a buddy-matching service.
Related JoVE Video
Coping-related variables associated with individual differences in adjustment to cancer.
J Psychosoc Oncol
PUBLISHED: 04-15-2010
Show Abstract
Hide Abstract
This study examined relationships between emotional adjustment and a number of coping styles and strategies in people with cancer. Two-hundred eighty-three adults completed measures of positive and negative emotions, subjective ratings of cancer-related symptoms and functional impairment, coping strategies, hope, benefit finding, emotional approach/avoidance, and cancer-related social support. Among the coping strategies, self-blame and behavioral disengagement were consistently associated with poor adjustment, while acceptance and humor were consistently associated with good adjustment. Among the broader measures of coping style, there were associations between poor adjustment and emotional processing, and between good adjustment and hope, benefit finding, and cancer-related social support.
Related JoVE Video
Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008.
Clin Colorectal Cancer
PUBLISHED: 01-27-2010
Show Abstract
Hide Abstract
The medical treatment of patients with metastatic colorectal cancer (mCRC) has evolved greatly in the past 10 years, involving complex combined chemotherapy protocols and, in more recent times, new biologic agents. Clinical benefit from the use of the targeted monoclonal antibodies bevacizumab, cetuximab, and panitumumab in the treatment of patients with mCRC is now well-established, but the optimal timing of their use requires careful consideration in order to derive the maximal benefit. Evidence to date suggests potentially distinct roles for bevacizumab and epidermal growth factor receptor-targeted biologic agents (cetuximab and panitumumab) in the treatment of patients with mCRC. This article reviews the evidence in support of modern treatments for mCRC and the decision making behind the treatment choices as well as their benefits and toxicities. An evidence-based algorithm is proposed that incorporates the use of these biologic agents early in the treatment of patients with initially nonresectable mCRC based on clearly defined tumor-related factors dependent on the immediate treatment goal. Real-world application of this algorithm is dependent on an individual countries approval of access to new biologic agents.
Related JoVE Video
Health-related quality of life in patients with advanced colorectal cancer treated with cetuximab: overall and KRAS-specific results of the NCIC CTG and AGITG CO.17 Trial.
J. Clin. Oncol.
PUBLISHED: 03-09-2009
Show Abstract
Hide Abstract
National Cancer Institute of Canada Clinical Trials Group CO.17 demonstrated the antiepidermal growth factor receptor (anti-EGFR) monoclonal antibody cetuximab improves overall and progression-free survival in patients with advanced, chemotherapy-refractory colorectal cancer (CRC), particularly in patients with wild-type KRAS tumors. This article reports the health-related quality-of-life (HRQL) outcomes from CO.17.
Related JoVE Video
Management of advanced gastric cancer.
Expert Rev Gastroenterol Hepatol
Show Abstract
Hide Abstract
The management of advanced gastric cancer has only evolved a little over the last 15 years: platinum and fluoropyrimidine chemotherapy remains the backbone of therapy with ongoing debate as to the benefit of triplet therapy with either an anthracycline or taxane. Recently published trials of biological agents, in particular those targeting the Her2 receptor, have provided some signs of improvement. This article summarizes the relevant literature, discusses the role of these agents, as well as geographical variations in use, and provides recommendations regarding both standard chemotherapy and the role of biological agents in advanced gastric cancer. Given the relative lack of progress for gastric cancer over the last 15 years, the focus for the next 5 years should be on an improved understanding of the molecular basis of gastric cancer, thus allowing rational integration of new molecular agents.
Related JoVE Video

What is Visualize?

JoVE Visualize is a tool created to match the last 5 years of PubMed publications to methods in JoVE's video library.

How does it work?

We use abstracts found on PubMed and match them to JoVE videos to create a list of 10 to 30 related methods videos.

Video X seems to be unrelated to Abstract Y...

In developing our video relationships, we compare around 5 million PubMed articles to our library of over 4,500 methods videos. In some cases the language used in the PubMed abstracts makes matching that content to a JoVE video difficult. In other cases, there happens not to be any content in our video library that is relevant to the topic of a given abstract. In these cases, our algorithms are trying their best to display videos with relevant content, which can sometimes result in matched videos with only a slight relation.